Perimeter Medical Imaging AI Inc

Perimeter Medical Imaging AI Inc has a current ratio of 4.07, indicating strong short-term liquidity, but its operating cash flow of -$3.57 million and free cash flow of -$1.97 million suggest ongoing cash burn. The company's debt-to-equity ratio is 0.01, reflecting minimal leverage and a conservative capital structure. However, the negative net cash position after subtracting total debt raises liquidity concerns. The company's profitability metrics are weak, with a return on equity of -16.72% and a return on assets of -13.1%, both significantly below the industry median for advanced medical equipment and technology firms. These figures indicate that the company is not generating returns that meet the cost of capital or industry benchmarks. Geographically, the company's revenue is concentrated in North America, with no disclosed international revenue segments. Its business is primarily driven by the healthcare equipment segment, with no material diversification across product lines or geographic regions. The company's revenue growth trajectory is uncertain, with no disclosed revenue growth in the most recent fiscal year. Analysts have assigned a mean price target of $1.82, with a median of $1.50, but no strong buy recommendations have been issued, reflecting cautious sentiment. The company's operating losses and negative cash flows suggest a challenging path to profitability in the near term. The company faces medium liquidity risk due to its negative operating cash flow and free cash flow, despite a low dilution risk. No dilution sources have been identified in the latest filings, and the company has not issued new shares recently. The absence of strong buy recommendations and the lack of positive cash flow metrics indicate a high degree of uncertainty in the company's valuation and future performance. Recent filings and transcripts have not disclosed any material events that would significantly alter the company's financial or operational outlook. The company remains in a development and commercialization phase, with ongoing investments in AI-based medical imaging solutions.